Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1552-1562

  Paine, Mary F ^a   Khalighi, Mehraneh ^a   Fisher, Jeannine M ^a   Shen, Danny D ^a   Kunze, Kent L ^a   Marsh, Christopher L ^b   Perkins, James D ^b   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME B5; CYTOCHROME P450 ISOENZYME; CYTOCHROME P450 REDUCTASE; MIDAZOLAM;

ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HYDROXYLATION; DRUG METABOLISM; DUODENUM; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; ILEUM; INTESTINE; JEJUNUM; MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL; TISSUE LEVEL;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; HUMANS; HYDROXYLATION; INTESTINES; LIVER; METABOLIC CLEARANCE RATE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0031445547     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. DE WAZIERS, I., CUGNENC, P. H., YANG, C. S., LEROUX, J.-P. AND BEAUNE, P. H.: Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253: 387-394, 1990.
2. FABRE, G., RAHMANI, R., PLACIDI, M., COMBALBERT, J., COVO, J., CANO, J.-P., COULANGE, C., DUCROS, M. AND RAMPAL, M.: Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem. Pharmacol. 37: 4389-4397, 1988.
3. FAVREAU, L. V., MALCOFF, D. M., MOLE, J. E. AND SCHENKMAN, J. B.: Responses to insulin by two forms of rat hepatic microsomal cytochrome P-450 that undergo major (RLM6) and minor (RLM5b) elevations in diabetes. J. Biol. Chem. 262: 14319-14326, 1987.
4. FROMM, M. F., BUSSE, D., KROEMER, H. K. AND EICHELBAUM, M.: Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24: 796-801, 1996.
5. GERVOT, L., CARRIÈRE, V., COSTET, P., CUGNENC, P.-H., BERGER, A., BEAUNE, P. H. AND DE WAZIERS, I.: CYP3A5 is the major cytochrome P450 CYP3A expressed in human colon and colonic cell lines. Environ. Toxicol. Pharmacol 2: 381-388, 1996.
6. GOMEZ, D. Y., WACHER, V. J., TOMLANOVICH, S. J., HEBERT, M. F. AND BENET, L. Z.: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 58: 15-19, 1995.
7. GORSKI, J. C., HALL, S. D., JONES, D. R., VANDENBRANDEN, M. AND WRIGHTON, S. A.: Regioselective biotransformation of midazolam by members of the human cytochrome P450 CYP3A (CYP3A) subfamily. Biochem. Pharmacol. 47: 1643-1653, 1994.
8. GUENGERICH, F. P.: Human cytochrome P450 enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry, 2nd ed., ed. by P. R. Ortiz de Montellano, pp. 473-535, Plenum Press, New York, 1995.
9. 14C-midazolam in humans following oral dosing. Arzneim.-Forsch. 31: 2220-2223, 1981.
10. HEBERT, M. F., ROBERTS, J. P., PRUEKSARITANONT, T. AND BENET, L. Z.: Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 52: 453-457, 1992.
11. HULTÉN, L., LINDHAGEN, J. AND LUNDGREN, O.: Sympathetic nervous control of intramural blood flow in the feline and human intestines. Gastroenterology 72: 41-48, 1977.
12. IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H., SHIMADA, N., CHIBA, K., ISHIZAKI, T., GREEN, C. E., TYSON, C. A. AND SUGIYAMA, Y.: Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73: 147-171, 1997.
13. JOUNAÏDI, Y., HYRAILLES, V., GERVOT, L. AND MAUREL, P.: Detection of CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein? Biochem. Biophys. Res. Commun. 221: 466-470, 1996.
14. KHARASCH, E. D. AND THUMMEL, K. E.: Human alfentanil metabolism by cytochrome P450 3A3/4: An explanation for the interindividual variability in alfentanil clearance? Anesth. Analg. 76: 1033-1039, 1993.
15. KIVISTO, K. T., BOOKJANS, G., FROMM, M. F., GRIESE, E.-U., MÜNZEL, P. AND KROEMER, H. K.: Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br. J. Clin. Pharmacol. 42: 387-389, 1996.
16. KOLARS, J. C., AWNI, W. M., MERION, R. M. AND WATKINS, P. B.: First-pass metabolism of cyclosporine by the gut. Lancet 338: 1488-1490, 1991.
17. KOLARS, J. C., LOWN, K. S., SCHMIEDLIN-REN, P., GHOSH, M., FANG, C., WRIGHTON, S. A., MERION, R. M. AND WATKINS, P. B.: CYP3A gene expression in human gut epithelium. Pharmacogenetics 4: 247-259, 1994.
18. KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. AND MEYER, U. A.: Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol. 36: 89-96, 1989.
19. KURZBAN, G. P. AND STROBEL, H. W.: Preparation and characterization of FAD-dependent NADPH-dependent cytochrome P-450 reductase. J. Biol. Chem. 261: 7824-7830, 1986.
20. LOWN, K. S., KOLARS, J. C., THUMMEL, K. E., BARNETT, J. L., KUNZE, K. L., WRIGHTON, S. A. AND WATKINS, P. B.: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab. Dispos. 22: 947-955, 1994.
21. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
22. MCKINNON, R. A., BURGESS, W. M., HALL, P. DE LA M., ROBERTS-THOMSON, S. J., GONZALEZ, F. J. AND MCMANUS, M. E.: Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36: 259-267, 1995.
23. MISTRY, M. AND HOUSTON, J. B.: Glucuronidation in vitro and in vivo: Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab. Disp. 15: 710-717, 1987.
24. OMURA, T. AND SATO, R.: The carbon monoxide-binding pigment of liver microsomes: II. Solubilization, purification and properties. J. Biol. Chem. 239: 2379-2385, 1964.
25. PACIFICI, G. M., FRANCHI, M., GERVASI, P. G., LONGO, V., DI SIMPLICIO, P., TEMELLINI, A. AND GIULIANI, L.: Profile of drug-metabolizing enzymes in human ileum and colon. Pharmacology 38: 137-145, 1989.
26. PAINE, M. F., SHEN, D. D., KUNZE, K. L., PERKINS, J. D., MARSH, C. L., MCVICAR, J. P., BARR, D. M., GILLIES, B. S. AND THUMMEL, K. E.: First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60: 14-24, 1996.
27. PETERS, W. H. M. AND KREMERS, P. G.: Cytochromes P-450 in the intestinal mucosa of man. Biochem. Pharmacol. 38: 1535-1538, 1989.
28. POND, S. M. AND TOZER, T. N.: First-pass elimination: Basic concepts and clinical consequences. Clin. Pharmacokinet. 9: 1-25, 1984.
29. PRUEKSARITANONT, T., GORHAM, L. M., HOCHMAN, J. H., TRAN, L. O. AND VYAS, K. P.: Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos. 24: 634-642, 1996.
30. ROWLAND, M., BENET, L. Z. AND GRAHAM, G. G.: Clearance concepts in pharmacokinetics. J. Pharmacokin. Biopharm. 1: 123-136, 1973.
31. SCHMUCKER, D. L., WOODHOUSE, K. W., WANG, R. K., WYNNE, H., JAMES, O. F., MCMANUS, M. AND KREMERS, P.: Effects of age and gender on the in vitro properties of human liver microsomal monooxygenases. Clin. Pharmacol. Ther. 48: 365-374, 1990.
32. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. AND GUENGERICH, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
33. SNYDER, W. S., COOK, M. J., NASSET, E. S., KARHAUSEN, L. R., HOWELLS, G. P. AND TIPTON, I. H.: Report of the Task Group on Reference Man, pp. 134-144, Pergamon Press, Oxford, 1975.
34. THUMMEL, K. E., KHARASCH, E. D., PODOLL, T. D. AND KUNZE, K. L.: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21: 350-357, 1993.
35. THUMMEL, K. E., KUNZE, K. L. AND SHEN, D. D.: Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug Deliv. Rev. 27: 99-127, 1997.
36. THUMMEL, K. E., O'SHEA, D., PAINE, M. F., SHEN, D. D., KUNZE, K. L., PERKINS, J. D. AND WILKINSON, G. R.: Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59: 491-502, 1996.
37. VAN GELDER, B. F. AND SLATER, E. C.: The extinction coefficient of cytochrome c. Biochim. Biophys. Acta 58: 593-595, 1962.
38. WATKINS, P. B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ-PICON, G., PARKER, G. A. AND GUZELIAN, P. S.: Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA 82: 6310-6314, 1985.
39. WATKINS, P. B., WRIGHTON, S. A., SCHUETZ, E. G., MOLOWA, D. T. AND GUZELIAN, P. S.: Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest. 80: 1029-1036, 1987.
40. WEBBER, I. R., PETERS, W. H. M. AND BACK, D. J.: Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br. J. Clin. Pharmacol. 33: 661-664, 1992.
41. WILKINSON, G. R.: Clearance approaches in pharmacology. Pharmacol. Rev. 39: 1-47, 1987.
42. WRIGHTON, S. A. AND STEVENS, J. C.: The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22: 1-21, 1992.